(1553189) Recurrent Genomic Alterations in the Apoptotic Machinery in Patients With CLL Treated With Venetoclax Monotherapy Following Treatment With BCRi

Primary Author; Presenting Author(s)

• 

  Jennifer A. Woyach, MD

  Professor of Medicine
  Division of Hematology, Department of Internal Medicine, The Ohio State University
  The Ohio State University Comprehensive Cancer Center
  Columbus, OH, United States

  Slides

Co-Author(s)

• RP

  Relja Popovic, PhD

  AbbVie Inc.
  North Chicago, IL, United States
• ER

  Emily Rossi, N/A

  AbbVie Inc.
  North Chicago, IL, United States
• SS

  Sanjana Singh, MA

  AbbVie Inc.
  North Chicago, IL, United States
• XW

  Xifeng Wang, PhD

  AbbVie Inc.
  North Chicago, IL, United States
• TO

  Toshihiko Oki, MD, PhD

  AbbVie Inc.
  North Chicago, IL, United States
• TR

  Tanya S. Rosenberg, PhD

  AbbVie Inc.
  North Chicago, IL, United States
• CQ

  Chen Qian, N/A

  AbbVie Inc.
  North Chicago, IL, United States
• MM

  Michael Moran, MA, PhD

  AbbVie Inc.
  North Chicago, IL, United States
• MB

  Michelle Boyer, PhD

  Genentech Inc
  San Francisco, CA, United States
• JJ

  Jeffrey Jones, PhD

  Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
  Columbus, OH, United States
• RF

  Richard R. Furman, MD

  Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine
  New York, NY, United States
• JG

  Jason Gotlib, MD

  Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
  Stanford, CA, United States
• SS

  Stephen J. Schuster, MD

  Lymphoma Program, Abramson Cancer Center, University of Pennsylvania
  Philadelphia, PA, United States
• BC

  Brenda Chyla, PhD

  Principal Research Scientist
  AbbVie Inc.
  North Chicago, IL, United States
• 

  Matthew S. Davids, MD, MMSc

  Director, Clinical Research, Division of Lymphoma
  Dana-Farber Cancer Institute (DFCI)
  Boston, MA, United States